IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#2751
Positioning
Market Dominance
Manufacturing
Medical Equipment
$2.5B
Simon D. Campion
DENTSPLY SIRONA Inc. designs, develops, manufactures, distributes, and sells various dental products. It offers dental equipment, imaging equipment, motorized dental handpieces, and other instruments. The company also provides dental CAD/CAM products, dental implant products, bone regenerative and restorative solutions, and educational programs.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Dates updated upon official exchange announcement.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$XRAY DENTSPLY SIRONA Inc. | 45 | 46 | 47 | 33 | - | - | -64.1% | -16.8% | 51.5% | -19.8% | -25.5% | -8.1% | 5.0% | 282.0x | $2.5B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
DENTSPLY SIRONA Inc. (XRAY) receives a "Reduce" rating with a composite score of 45.3/100. It ranks #2751 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for XRAY.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 46 | 37 | +9ALPHA |
| MOMENTUM | 33 | 22 | +11ALPHA |
| VALUATION | 47 | 37 | +10ALPHA |
| INVESTMENT | 32 | 48 | -16DRAG |
| STABILITY | 60 | 57 | +3NEUTRAL |
| SHORT INT | 51 | 54 | -3NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -8.5% vs WACC 5.4% (spread -13.8%)
GM 52% vs sector 44%, OM -20% vs sector 3%
Capital turnover 0.44x, R&D intensity 4.0%
Rev growth -8%, 10yr history
Interest coverage -9.5x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate DENTSPLY SIRONA Inc. (XRAY) as a Reduce with a composite score of 45.3/100 at a current price of $13.13. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential.
DENTSPLY SIRONA Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 45.3/100 places it at rank #2751 in our full universe.
No Moat
High
Poor
Fair Value
Gross margins of 52% signal strong pricing power.
Stable competitive position in a defensive sector.
Leverage of 282% D/E amplifies downside risk.
Weak momentum suggests persistent institutional selling pressure.
Vulnerability to macroeconomic shocks and interest rate volatility.
DENTSPLY SIRONA Inc. represents a reduce based on multi-factor quantitative performance.
DENTSPLY SIRONA Inc. receives a Reduce rating from our analysis, with a composite score of 45.3/100 and 2 out of 5 stars, ranking #2751 out of 7,333 stocks. XRAY's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 46/100, XRAY shows adequate but unremarkable business quality. The company reports a return on equity of -64.1% (sector avg: -1.9%), gross margins of 51.5% (sector avg: 44.1%), net margins of -25.5% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
With a value score of 47/100, XRAY appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 1.69x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
DENTSPLY SIRONA Inc.'s investment score of 32/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of -8.1% vs. a sector average of 6.7% and a return on assets of -16.8% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
XRAY is currently showing below-average momentum at 33/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at -8.1% year-over-year, while a beta of 1.15 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 60/100, XRAY exhibits average financial resilience. Key stability metrics include a beta of 1.15 and a debt-to-equity ratio of 282.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
The short interest score of 51/100 for XRAY suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include elevated leverage (D/E: 282.00x). With a $2.5B market cap (mid-cap), DENTSPLY SIRONA Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
DENTSPLY SIRONA Inc. offers an attractive dividend yield of 5.0%, placing it among the higher-yielding stocks in its peer group. A yield this high can provide meaningful income, but investors should verify the payout is sustainable by examining the payout ratio, free cash flow coverage, and any history of dividend cuts.
DENTSPLY SIRONA Inc. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #2751 of 7,333 overall (62nd percentile). Key comparisons include ROE of -64.1% trailing the -1.9% sector median and operating margins of -19.8% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While XRAY currently exhibits a REDUCE profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (32) would have the largest impact on the composite score.
ROE 3276% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 17% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 889% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
DENTSPLY SIRONA (NasdaqGS:XRAY) expanded its partnership with Burkhart Dental Supply to include its full technology portfolio. The agreement brings intraoral scanners, imaging systems, and restorative technologies into Burkhart’s offering to dental practices. The move is aimed at broadening access to Dentsply Sirona’s digital dentistry solutions across Burkhart’s customer network. DENTSPLY SIRONA comes into this expanded partnership with a mixed share price record. The stock trades at...
New directors bring decades of financial leadership and board experience to enhance strategic oversight of Return-to-Growth action plan and long-term value creationCHARLOTTE, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced the appointments of James (Jim) D. Forbes and Brian P. McKeon to its Board of Directors (the “Board”), effective February 27, 2026. Mr. Forbes is a veteran healthcare investment banker with 30 yea
Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.